Belite Bio (BLTE) reported a Q2 non-GAAP net loss Wednesday of $0.54 per diluted share, widening from a loss of $0.27 a year earlier.

An analyst polled by FactSet expected a loss of $0.54.

As of June 30, the company had cash, cash equivalents, and US treasury bills and notes of $780 million.